Evidence map›Paper›PMID 36138151›Full record

ArticleNature medicine2022

Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.

Rebecca C Simpson, Erin R Shanahan, Marcel Batten, Irene L M Reijers, Mark Read, Ines P Silva, Judith M Versluis, Rosilene Ribeiro, Alexandra S Angelatos, Jian Tan and 20 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 153 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
153citing papers in PubMed, 5 pooled it
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

153 citing papers in PubMed, 5 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Gut microbiota modulation of systemic immunity and cancer immunotherapy: mechanisms, evidence, and therapeutic implications.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

93 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 3 institutions in 3 countries.

Rebecca C Simpson *Melanoma Institute Australia, The University of Sydney, Sydney, Australia.
Erin R Shanahan *Charles Perkins Centre, The University of Sydney, Sydney, Australia.
Marcel Batten *Melanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-3726-3790
Irene L M ReijersDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mark ReadCharles Perkins Centre, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-1481-4780
Ines P SilvaMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Judith M VersluisDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Rosilene RibeiroCharles Perkins Centre, The University of Sydney, Sydney, Australia.
Alexandra S AngelatosCharles Perkins Centre, The University of Sydney, Sydney, Australia.
Jian TanCharles Perkins Centre, The University of Sydney, Sydney, Australia.
Chandra AdhikariMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Alexander M MenziesMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Robyn P M SawMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-3354-806X
Maria GonzalezMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Kerwin F ShannonMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-8538-3132
Andrew J SpillaneMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Rebecca VelickovicMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Alexander J LazarDepartment of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6395-4499
Ashish V DamaniaPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aditya K MishraPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Manoj ChelvanambiDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-2130-3118
Anik BanerjeeThe University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Nadim J AjamiPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jennifer A WargoPlatform for Innovative Microbiome and Translational Research, Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3438-7576
Laurence MaciaCharles Perkins Centre, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-0835-851X
Andrew J HolmesCharles Perkins Centre, The University of Sydney, Sydney, Australia.
James S WilmottMelanoma Institute Australia, The University of Sydney, Sydney, Australia.
Christian U BlankDepartment of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0002-7945-5846
Richard A ScolyerMelanoma Institute Australia, The University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-8991-0013
Georgina V LongMelanoma Institute Australia, The University of Sydney, Sydney, Australia. georgina.long@sydney.edu.au.ORCID http://orcid.org/0000-0001-8894-3545
The University of Sydney · AUThe University of Texas MD Anderson Cancer Center · USThe Netherlands Cancer Institute · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gut microbiota shapes the response to immune checkpoint inhibitors (ICIs) in cancer, however dietary and geographic influences have not been well-studied in prospective trials. To address this, we prospectively profiled baseline gut (fecal) microbiota signatures and dietary patterns of 103 trial patients from Australia and the Netherlands treated with neoadjuvant ICIs for high risk resectable metastatic melanoma and performed an integrated analysis with data from 115 patients with melanoma treated with ICIs in the United States. We observed geographically distinct microbial signatures of response and immune-related adverse events (irAEs). Overall, response rates were higher in Ruminococcaceae-dominated microbiomes than in Bacteroidaceae-dominated microbiomes. Poor response was associated with lower fiber and omega 3 fatty acid consumption and elevated levels of C-reactive protein in the peripheral circulation at baseline. Together, these data provide insight into the relevance of native gut microbiota signatures, dietary intake and systemic inflammation in shaping the response to and toxicity from ICIs, prompting the need for further studies in this area.

Indexed as

Gastrointestinal MicrobiomeMelanomaDietHumansImmunotherapyProspective Studies

Identifiers

PMID36138151
OpenAlexW4296681502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.